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Introduction {#sec005}
============

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-associated mortality globally \[[@pone.0223530.ref001]--[@pone.0223530.ref002]\], and approximately 15% to 50% of NSCLC patients have an activating epidermal growth factor receptor (EGFR) mutation \[[@pone.0223530.ref003]\]. First-generation tyrosine kinase inhibitors (F-TKIs) (gefitinib, erlotinib, or icotinib) have consistently shown a progression-free survival (PFS) benefit compared to chemotherapy (CT) in first-line of treatment of advanced EGFR-mutated NSCLC \[[@pone.0223530.ref004]--[@pone.0223530.ref010]\]. Recently, the survival differences between F-TKIs, second-generation TKIs (S-TKIs) (afatinib or dacomitinib), and third-generation TKI (osimertinib) have been investigated in a number of trials \[[@pone.0223530.ref011]--[@pone.0223530.ref015]\]. Most of the trials have demonstrated the benefit of S-TKIs and osimertinib over F-TKIs in previously treated advanced EGFR-mutated NSCLC. Promising results also have been reported for F-TKIs in combination with CT (F-TKIs+CT) \[[@pone.0223530.ref016]--[@pone.0223530.ref019]\] or Bevacizumab (F-TKIs+Bev) \[[@pone.0223530.ref020]--[@pone.0223530.ref022]\]. However, direct comparison trials between S-TKIs, T-TKIs, and combination regimens involving TKIs are still lacking, and therefore, there are still unresolved questions around which is the optimal first-line treatment for patients with advanced EGFR-mutated NSCLC.

Two previous network meta-analyses \[[@pone.0223530.ref023]--[@pone.0223530.ref024]\] have evaluated first-line treatments in advanced EGFR-mutated NSCLC. However, first-line treatment of osimertinib has not been assessed in Lin et al' study \[[@pone.0223530.ref023]\], while first-line treatment of combination regimens involving TKIs has not been evaluated in Batson et al' study \[[@pone.0223530.ref024]\]. Moreover, since the two meta-analyses, several available RCTs \[[@pone.0223530.ref019], [@pone.0223530.ref022], [@pone.0223530.ref025]\] have been newly published. Thus, we performed a novel network meta-analysis, attempting to identify the most preferable first-line treatment regimen in patients with advanced EGFR-mutated NSCLC.

Methods {#sec006}
=======

This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria \[[@pone.0223530.ref026]\] ([S1 Table](#pone.0223530.s004){ref-type="supplementary-material"}).

Literature search strategy {#sec007}
--------------------------

Two investigators independently searched PubMed, Embase, Cochrane Library, Web of Science, and major international scientific meetings (American Society of Clinical Oncology, European Society for Medical Oncology, and World Conference on Lung Cancer) for the available trials published before March 1, 2019. The detailed strategies are shown in [S2 Table](#pone.0223530.s005){ref-type="supplementary-material"}.

Inclusion and exclusion criteria {#sec008}
--------------------------------

Studies meeting the following criteria were included: (1) types of studies: randomized controlled trials (RCTs); (2) types of participants: advanced EGFR-mutated NSCLC patients; (3) types of interventions: at least one intervention was a TKI (F-TKIs, S-TKIs, or osimertinib), alone or in combination with other types of treatments; and (4) outcome: reported PFS or overall survival (OS) data. Studies which failed to meet the above criteria were excluded from the network meta-analysis.

Data extraction {#sec009}
---------------

Two investigators extracted the following data from each study independently: first author or RCT name, year of publication, duration of RCT, region, interventions, numbers of patients, hazard ratios (HRs) and their 95% confidence intervals (CIs) of PFS and OS, and odds ratios (ORs) and their 95% CIs of serious adverse events (SAEs). Crude HRs with 95% CIs for PFS and OS were either extracted directly from the original reports or calculated by the Kaplan--Meier curves based on the methods of Parmar et al. \[[@pone.0223530.ref027]\] and Tierney et al. \[[@pone.0223530.ref028]\]. Data on the overall numbers of patients with SAEs were directly extracted if they were reported in the published article. If only the numbers of individual SAEs were reported separately in articles, we pooled all numbers of them to represent the overall numbers of SAEs.

Quality assessment {#sec010}
------------------

Cochrane risk of bias tool \[[@pone.0223530.ref029]\] was used to evaluate the methodological quality of RCTs, which includes the following five domains: sequence generation, allocation concealment, blinding, incomplete data, and selective reporting. A RCT was rated as "low risk of bias" if all key domains indicated as low risk, was rated as "high risk of bias" if one or more key domains indicated as high risk, and was judged to be "unclear risk of bias" when more than three domains indicated as unclear risk.

Statistical analysis {#sec011}
--------------------

The primary outcome was PFS, and the secondary outcomes were OS and SAEs. For direct comparisons, standard pairwise meta-analysis (PWMA) was performed. The heterogeneity between studies was assessed by chi-square (χ^2^) and *I*-square (*I*^2^) tests. A *P* value \<0.10 or *I*^2^ \> 50% was considered significant heterogeneity existing, and a random-effects analysis model was used; otherwise, a fixed-effects model was used. PWMA was performed using the software Review Manager 5.3 (Cochrane Collaboration, Oxford, UK).

The Bayesian network-meta analysis (NMA) for all outcomes were performed in a random-effect model \[Generalized Linear Model (GLM)\] using Markov chain Monte Carlo methods \[[@pone.0223530.ref030]--[@pone.0223530.ref031]\] in JAGS and the GeMTC package in R (<https://drugis.org/software/r-packages/gemtc>). OS and PFS were analyzed with GLM with a normal likelihood incorporating log hazard ratio statistics from individual trials to calculate HR between competing treatments. Count statistics of SAEs was analyzed with GLM with a binomial likelihood to calculate relative treatment effects expressed as OR between different treatments. For each outcome measure, four independent Markov chains were simultaneously run for 20,000 burn-ins and 100,000 inference iterations per chain to obtain the posterior distribution. The traces plot and Brooks-Gelman-Rubin method were used to assess the convergence of model \[[@pone.0223530.ref032]\]. Treatment effects were estimated by HR/OR and corresponding 95% CI. Network consistency was assessed with node-split models by statistically testing between direct and indirect estimates within treatment loop \[[@pone.0223530.ref033]\]. To rank probabilities of all available treatments, the surfaces under the cumulative ranking curve (SUCRAs) were calculated \[[@pone.0223530.ref034]\]. SUCRA equals one if the treatment is certain to be the best and zero if it's certain to be the worst \[[@pone.0223530.ref034]\]. To jointly compare the efficacy and tolerability of each treatment and to assess their benefit-risk ratios, we ranked them based simultaneously on the SUCRA value of PFS and tolerability (1-SUCRA~SAEs~) in the ranking plot. Lastly, comparison-adjusted funnel plot was used to detect the presence of small-study effects or publication bias.

Results {#sec012}
=======

Literature search results and characteristics of included studies {#sec013}
-----------------------------------------------------------------

[Fig 1](#pone.0223530.g001){ref-type="fig"} shows the flow diagram for study selection. The preliminary literature search identified 13725 studies. 13471 of them were excluded after removing the duplicates and an abstract review. The remaining 254 studies were screened through a full-text review for further eligibility. All relevant references were also reviewed. Finally, 25 RCTs \[[@pone.0223530.ref004]--[@pone.0223530.ref022], [@pone.0223530.ref025], [@pone.0223530.ref035]--[@pone.0223530.ref047]\] with 5005 patients were included in the network meta-analysis and compared seven treatments including F-TKIs, S-TKIs, osimertinib, CT, F-TKIs+CT, F-TKIs+Bev, and F-TKIs+Linsitinib (F-TKIs+Lin). The clinical characteristics are shown in [Table 1](#pone.0223530.t001){ref-type="table"}.

![Literature search and selection.](pone.0223530.g001){#pone.0223530.g001}

10.1371/journal.pone.0223530.t001

###### Clinical characteristics of included trials.

![](pone.0223530.t001){#pone.0223530.t001g}

  Trial                                                               Design   Time         Region          Primary   Treatment     Sample   Median follow-up
  ------------------------------------------------------------------- -------- ------------ --------------- --------- ------------- -------- ------------------
  NEJ002/2010\[[@pone.0223530.ref004]--[@pone.0223530.ref005]\]       III      2006--2009   Multicenter     PFS       F-TKIs        114      \>17
                                                                                                                      CT            114      
  WJTOG3405/2010\[[@pone.0223530.ref006]--[@pone.0223530.ref007]\]    III      2006--2009   Japan           PFS       F-TKIs        86       34
                                                                                                                      CT            86       
  EURTAC/2012\[[@pone.0223530.ref008]\]                               III      2007--2011   Multicenter     PFS       F-TKIs        86       18.9
                                                                                                                      CT            87       14.4
  OPTIMAL/2011\[[@pone.0223530.ref009]--[@pone.0223530.ref010]\]      III      2011--2014   China           PFS       F-TKIs        82       25.9
                                                                                                                      CT            72       
  LUX-Lung7/2016\[[@pone.0223530.ref011]--[@pone.0223530.ref012]\]    II       2011--2013   Multicenter     PFS       S-TKIs        160      42.6
                                                                                                                      F-TKIs        159      
  ARCHER1050/2017\[[@pone.0223530.ref013]--[@pone.0223530.ref014]\]   III      2013--2015   Asian           PFS       S-TKIs        227      22.1
                                                                                                                      F-TKIs        225      
  FLAURA/2017\[[@pone.0223530.ref015]\]                               III      2014--2016   Multicenter     PFS       Osimertinib   279      15
                                                                                                                      F-TKIs        277      9.7
  FASTACT-2/2013\[[@pone.0223530.ref016]\]                            II       2009--2010   Asian           PFS       F-TKIs+CT     49       27.6
                                                                                                                      CT            48       
  Yu/2014\[[@pone.0223530.ref017]\]                                   II       2010--2012   China           ORR       F-TKIs+CT     14       NR
                                                                                                                      CT            18       
  Cheng/2016\[[@pone.0223530.ref018]\]                                II       2012--2013   Asian           PFS       F-TKIs+CT     126      NR
                                                                                                                      F-TKIs        65       
  NEJ009/2018\[[@pone.0223530.ref019]\]                               III      2011--2014   Japan           PFS       F-TKIs+CT     172      NR
                                                                                                                      F-TKIs        170      
  JO25567/2014\[[@pone.0223530.ref020]--[@pone.0223530.ref021]\]      II       2011--2012   Japan           PFS       F-TKIs+Bev    75       25.9
                                                                                                                      F-TKIs        77       27
  NEJ026/2018\[[@pone.0223530.ref022]\]                               III      NR           Japan           PFS       F-TKIs+Bev    112      12.4
                                                                                                                      F-TKIs        112      
  CONVINCE/2017\[[@pone.0223530.ref025]\]                             III      2013--2014   China           PFS       F-TKIs        148      18
                                                                                                                      CT            137      15.7
  IPASS/2009\[[@pone.0223530.ref035]--[@pone.0223530.ref036]\]        III      2005--2008   Asian           PFS       F-TKIs        132      17
                                                                                                                      CT            129      
  TORCH/2012\[[@pone.0223530.ref037]\]                                III      2006--2009   Italy, Canada   OS        F-TKIs        19       24.3
                                                                                                                      CT            20       
  Chen/2012\[[@pone.0223530.ref038]\]                                 II       2007--2008   China           PFS       F-TKIs        9        NR
                                                                                                                      CT            15       
  ENSURE/2015\[[@pone.0223530.ref039]\]                               III      2011--2012   Asian           PFS       F-TKIs        110      28.9
                                                                                                                      CT            107      27.1
  Han/2012\[[@pone.0223530.ref040]\]                                  III      2005--2007   Korea           OS        F-TKIs        26       35
                                                                                                                      CT            16       
  LUX-Lung3/2013\[[@pone.0223530.ref041]--[@pone.0223530.ref042]\]    III      2009--2011   Multicenter     PFS       S-TKIs        230      41
                                                                                                                      CT            115      
  LUX-Lung6/2014\[[@pone.0223530.ref042]--[@pone.0223530.ref043]\]    III      2010--2011   Asian           PFS       S-TKIs        242      33
                                                                                                                      CT            122      
  Hirsch/2011\[[@pone.0223530.ref044]\]                               II       2007--2008   Multicenter     PFS       F-TKIs+CT     6        NR
                                                                                                                      F-TKIs        9        
  CALGB30406/2012\[[@pone.0223530.ref045]\]                           II       2005--2009   United States   PFS       F-TKIs+CT     33       38
                                                                                                                      F-TKIs        33       
  TRIBUTE/2005\[[@pone.0223530.ref046]\]                              III      2001--2002   United States   OS        F-TKIs+CT     93       NR
                                                                                                                      CT            74       NR
  Leighl/2017\[[@pone.0223530.ref047]\]                               II       NR           Multicenter     PFS       F-TKIs+Lin    44       NR
                                                                                                                      F-TKIs        44       

Abbreviations: PFS, progression-free survival; OS, overall survival; ORR, overall response rate; NR, not reported; TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.

Assessment of included trial {#sec014}
----------------------------

The demographic characteristics of involved patients were generally well-balanced between different trials and different arms within each trial (see [S3 Table](#pone.0223530.s006){ref-type="supplementary-material"}). Median age ranged from 56 to 68 years. 22--44% of patients were male; and 0--14% were with squamous cell carcinoma. Most of patients were with Stage IV disease (73.2--100%), except patients included in WJTOG3405 trial (47.7%) \[[@pone.0223530.ref006]--[@pone.0223530.ref007]\]. EGFR mutations were mainly exon 19 deletions and 21 deletions mutations. In eleven studies, details of baseline demographic characteristics were not stated \[[@pone.0223530.ref016]--[@pone.0223530.ref017], [@pone.0223530.ref035]--[@pone.0223530.ref038], [@pone.0223530.ref040], [@pone.0223530.ref044]--[@pone.0223530.ref046]\]. The risk of bias in included RCTs was summarized in [S1 Fig](#pone.0223530.s001){ref-type="supplementary-material"}. Four RCTs \[[@pone.0223530.ref004]--[@pone.0223530.ref005], [@pone.0223530.ref017], [@pone.0223530.ref019], [@pone.0223530.ref022]\] were judged to be unclear risk of bias, as they had more than three domains indicating as unclear risk. The remaining RCTs were judged to be low risk of bias. No trial was rated with a high risk of bias. Funnel plot analysis in term of PFS did not indicate any evident risk of publication bias ([S2 Fig](#pone.0223530.s002){ref-type="supplementary-material"}).

Conventional pairwise meta-analysis {#sec015}
-----------------------------------

Results of individual trials are shown in S4 table. Results of PWMA are shown in [Table 2](#pone.0223530.t002){ref-type="table"}. In terms of PFS, S-TKIs (HR = 0.65, 95% CI: 0.54--0.77, *P*~heterogeneity~ = 0.23), F-TKIs+CT (HR = 0.57, 95% CI: 0.47--0.70, *P*~heterogeneity~ = 0.22), and F-TKIs+Bev (HR = 0.56, 95% CI: 0.43--0.74, *P*~heterogeneity~ = 0.55) were more effective than F-TKIs. With regard to OS, S-TKIs showed significant advantage over F-TKIs (HR = 0.81, 95% CI: 0.67--0.97, *P*~heterogeneity~ = 0.52). As for overall SAEs, S-TKIs (OR = 2.29, 95% CI: 1.69--3.12, *P*~heterogeneity~ = 0.58), F-TKIs+CT (OR = 3.79, 95% CI: 2.58--5.56, *P*~heterogeneity~ = 0.58), and F-TKIs+Bev (OR = 4.05, 95% CI: 1.04--15.86, *P*~heterogeneity~ = 0.009) were more likely to cause SAEs than F-TKIs.

10.1371/journal.pone.0223530.t002

###### Results of direct comparisons.

![](pone.0223530.t002){#pone.0223530.t002g}

  Outcome   Treatment              No. of   No. of   HR/OR(95%CI)           Heterogeneity   
  --------- ---------------------- -------- -------- ---------------------- --------------- ---------
  PFS       S-TKIs vs F-TKIs       2        771      HR 0.65(0.54--0.77)    31%             0.23
            F-TKIs+CT vs F-TKIs    4        614      HR 0.57(0.47--0.70)    32%             0.22
            F-TKIs+Bev vs F-TKIs   2        376      HR 0.56(0.43--0.74)    0               0.55
            F-TKIs vs CT           10       1595     HR 0.46(0.29--0.72)    93%             \<0.001
            F-TKIs+CT vs CT        2        129      HR 0.24(0.16--0.37)    0               0.75
            S-TKIs vs CT           2        709      HR 0.40(0.20--0.83)    90%             0.001
  OS        S-TKIs vs F-TKIs       2        771      HR 0.81(0.67--0.97)    0               0.52
            F-TKIs vs CT           9        1423     HR 1.01(0.88--1.15)    0               0.87
            S-TKIs vs CT           2        709      HR 0.91(0.74--1.10)    0               0.78
            F-TKIs+CT vs F-TKIs    2        408      HR 0.70(0.54--0.92)    0               0.93
            F-TKIs+CT vs CT        2        264      HR 0.71(0.35--1.46)    78%             0.03
  SAEs      S-TKIs vs F-TKIs       2        771      OR 2.29(1.69--3.12)    0               0.58
            F-TKIs+CT vs F-TKIs    2        533      OR 3.79(2.58--5.56)    0               0.58
            F-TKIs+Bev vs F-TKIs   2        376      OR 4.05(1.04--15.86)   85%             0.009
            F-TKIs vs CT           6        1229     OR 0.30(0.21--0.43)    48%             0.09
            S-TKIs vs CT           2        709      OR 0.68(0.21--2.22)    92%             \<0.001

Abbreviations: No., number; HR, hazard ratio; CI, confidence interval; OR, odds ratio; PFS, progression-free survival; OS, overall survival; SAEs, serious adverse events; TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy.

Network meta-analysis {#sec016}
---------------------

The network plot established for NMA is shown in [Fig 2](#pone.0223530.g002){ref-type="fig"}. Results of the NMA were presented in [Table 3](#pone.0223530.t003){ref-type="table"}. Osimertinib and F-TKIs+CT were more effective than F-TKIs in terms of PFS (HR = 0.46, 95% CI: 0.23--0.93; *P* = 0.031 and HR = 0.62, 95% CI: 0.39--0.98; *P* = 0.041) and OS (HR = 0.63, 95% CI: 0.43--0.91; *P* = 0.014 and HR = 0.73, 95% CI: 0.57--0.92; *P* = 0.008). S-TKIs showed significant OS advantage over F-TKIs (HR = 0.83, 95% CI: 0.70--0.99; *P* = 0.04). Other comparisons among TKIs based regimens in terms of PFS or OS did not produce statistically significant differences. With regard to overall SAEs, osimertinib showed significantly lower risk of causing SAEs in comparison to each TKIs based regimens except F-TKIs; F-TKIs had significantly lower risk of causing SAEs than each TKIs based regimens except osimertinib. No significant differences were observed in other comparisons between TKIs based regimens in terms of SAEs.

![Network of eligible comparisons.\
The size of the nodes is proportional to the number of patients (in parentheses) randomized to receive the treatment. The width of the lines is proportional to the number of trials (beside the line) comparing the connected treatments. TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.](pone.0223530.g002){#pone.0223530.g002}

10.1371/journal.pone.0223530.t003

###### Results of network meta-analysis.

![](pone.0223530.t003){#pone.0223530.t003g}

  --------------------------------------------------------------------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ------------------ ----
  a\. Hazard ratios(HR) with 95% confidence interval (CI) for progression-free survival (PFS)                                                                                                                  
  Osimertinib                                                                                                                                                                                                  
  0.75(0.28--2.0)                                                                               F-TKIs+CT                                                                                                      
  0.74(0.25--2.3)                                                                               0.99(0.45--2.2)        F-TKIs+Bev                                                                              
  0.60(0.22--1.6)                                                                               0.80(0.43--1.5)        0.80(0.36--1.8)        S-TKIs                                                           
  **0.46(0.23--0.93)**                                                                          **0.62(0.39--0.98)**   0.62(0.32--1.2)        0.77(0.48--1.2)        F-TKIs                                    
  0.34(0.09--1.3)                                                                               0.45(0.15--1.4)        0.46(0.13--1.5)        0.57(0.18--1.7)        0.73(0.26--2.0)        F-TKIs+Lin         
  **0.20(0.10--0.43)**                                                                          **0.27(0.18--0.41)**   **0.27(0.15--0.50)**   **0.34(0.23--0.50)**   **0.44(0.35--0.56)**   0.61(0.24--1.52)   CT
  b\. Hazard ratios(HR) with 95% confidence interval (CI) for overall survival(OS)                                                                                                                             
  Osimertinib                                                                                                                                                                                                  
  0.87(0.56--1.3)                                                                               F-TKIs+CT                                                                                                      
  0.78(0.43--1.4)                                                                               0.90(0.54--1.5)        F-TKIs+Bev                                                                              
  0.76(0.50--1.1)                                                                               0.87(0.66--1.2)        0.97(0.60--1.6)        S-TKIs                                                           
  **0.63(0.43--0.91)**                                                                          **0.73(0.57--0.92)**   0.81(0.51--1.3)        **0.83(0.70--0.99)**   F-TKIs                                    
  0.82(0.25--2.8)                                                                               0.95(0.29--3.1)        1.1(0.31--3.7)         1.1(0.34--3.5)         1.3(0.42--4.2)         F-TKIs+Lin         
  **0.65(0.46--0.93)**                                                                          **0.76(0.61--0.95)**   0.84(0.54--1.31)       0.87(0.75--1.01)       1.04(0.93--1.17)       0.80(0.25--2.58)   CT
  c\. Odds ratios (OR) with 95% confidence interval (CI) for serious adverse events (SAEs)                                                                                                                     
  Osimertinib                                                                                                                                                                                                  
  **0.18(0.06--0.56)**                                                                          F-TKIs+CT                                                                                                      
  **0.18(0.06--0.58)**                                                                          1.01(0.36--2.82)       F-TKIs+Bev                                                                              
  **0.30(0.11--0.81)**                                                                          1.62(0.69--3.84)       1.61(0.65--3.97)       S-TKIs                                                           
  0.67(0.28--1.61)                                                                              **3.68(1.83--7.41)**   **3.65(1.72--7.74)**   **2.27(1.38--3.73)**   F-TKIs                                    
  **0.19(0.04--0.85)**                                                                          1.03(0.25--4.23)       1.03(0.24--4.31)       0.64(0.17--2.39)       **0.28(0.08--0.95)**   F-TKIs+Lin         
  0.20(0.08--0.52)                                                                              1.10(0.49--2.43)       1.09(0.47--2.52)       0.67(0.41--1.11)       0.30(0.20--0.43)       1.06(0.29--3.82)   CT
  --------------------------------------------------------------------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ------------------ ----

Abbreviations: For survival outcomes (OS, PFS), an HR below 1 favors the column-defining treatment. For safety (SAEs), an OR below 1 favors the column-defining treatment. Comparisons with differences of statistical significance (p\<0.05) are highlighted in bold format. TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.

Inconsistency assessment and treatment ranking {#sec017}
----------------------------------------------

There were two independent closed loops in the network for PFS or OS: F-TKIs/S-TKIs/CT and F-TKIs/F-TKIs+CT/CT; one independent closed loop for SAEs: F-TKIs/S-TKIs/CT. Analysis of inconsistency showed that the NMA results were similar to the PWMA results for the three outcomes, which suggested the consistency between the direct and indirect evidence ([S3 Fig](#pone.0223530.s003){ref-type="supplementary-material"}).

The treatment rankings based on SUCRA are shown in [Fig 3](#pone.0223530.g003){ref-type="fig"}. In term of PFS ([Fig 3A](#pone.0223530.g003){ref-type="fig"}), osimertinib was the most effective treatment (0.89), followed by F-TKIs+CT (0.75), F-TKIs+Bev (0.73), and S-TKIs (0.56). With regard to OS ([Fig 3B](#pone.0223530.g003){ref-type="fig"}), osimertinib was still the most effective treatment (0.86), followed by F-TKIs+CT (0.71), F-TKIs+Lin (0.54), and F-TKIs+Bev (0.53). As for SAEs ([Fig 3C](#pone.0223530.g003){ref-type="fig"}), osimertinib was ranked as the least toxic regimen (0.96), followed by F-TKIs (0.86) and S-TKIs (0.57); F-TKIs+CT (0.25) was ranked as the highest toxic regimen.

![The treatment rankings based on SUCRA.\
(a) progression-free survival; (b) overall survival; (c) serious adverse events. SUCRA, surface under the cumulative ranking curves; TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.](pone.0223530.g003){#pone.0223530.g003}

To further assess the benefit-risk ratios of the seven treatments simultaneously, we ranked them based on the SUCRA values of PFS and tolerability (31-SUCRA ~SAE~) in the ranking plot ([Fig 4](#pone.0223530.g004){ref-type="fig"}). Osimertinib was likely to be the optimal treatment because it had the most efficacy and best tolerability. F-TKIs+CT and F-TKIs+Bev were also two more effective regimens, but with relatively high risk of causing SAEs. S-TKIs achieved relatively good efficacy with moderate tolerability.

![Ranking plot based simultaneously on efficacy (x-axis: SUCRA value of overall survival) and tolerability (y-axis: 1-SUCRA value of serious adverse events).\
SUCRA, surface under the cumulative ranking curves; TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.](pone.0223530.g004){#pone.0223530.g004}

Discussion {#sec018}
==========

This novel network meta-analysis assessed the comparative efficacy and tolerability of all major TKIs based first-line treatments (including first-, second-, third-generation TKIs, and combination regimens involving TKIs) in advanced EGFR-mutated NSCLC. It showed that osimertinib provided significant PFS and OS advantage over F-TKIs, and had the highest probability of being the most effective treatment in improving PFS and OS, and with the best tolerability. In the FLAURA study \[[@pone.0223530.ref015]\] comparing first-line osimertinib with gefitinib or erlotinib in patients with advanced EGFR-mutated NSCLC, the median PFS (mPFS) was significantly longer with osimertinib than with standard F-TKIs (18.9 versus 10.0 months, *P* \< 0.001). Overall SAEs were less frequent with osimertinib than with F-TKIs (34% vs. 45%).

F-TKIs+CT and F-TKIs+Bev were another two more effective regimens in our NMA. Based on treatment ranking, they were ranked second- and third- most effective regimen respectively, but with relatively high risk of causing SAEs. The NEJ009 study, a phase III trial evaluated the efficacy of a combination of gefitinib and CT in advanced NSCLC patients with EGFR mutations \[[@pone.0223530.ref018]\]. The combination arm demonstrated significantly improved mPFS (20.9 versus 11.2 months, *P* \< 0.001) and median OS (mOS) (52.2 versus 38.8 months, P = 0.013) compared with gefitinib alone arm. A phase II study \[[@pone.0223530.ref020]--[@pone.0223530.ref021]\] comparing combination of erlotinib and bevacizumab with erlotinib alone in this patient population reported results with significant benefit on mPFS (16.4 versus 9.8 months, *P* = 0.0005). Similar improved mPFS was also observed in a phase III trial (NEJ026) \[[@pone.0223530.ref022]\] (16.9 months in erlotinib+bevacizumab arm versus 13.3 months in erlotinib alone arm, *P* \< 0.001). Although both the two combination regimens were associated with higher incidence of grade 3 toxicities, few patients required dose reduction or withdrawal.

The survival difference between F-TKIs and S-TKIs has been investigated in two trials. LUX-LUNG 7 trial \[[@pone.0223530.ref011]--[@pone.0223530.ref012]\] showed no clinically meaningful survival benefit with afatinib versus with gefitinib in patients with advanced EGFR-mutated NSCLC. However, in another phase III trial \[[@pone.0223530.ref013]--[@pone.0223530.ref014]\] comparing dacomitinib with gefitinib in patients with EGFR-mutated NSCLC without brain metastases, dacomitinib was associated with significant improvement in mPFS (14.7 versus 9.2 months, *P* \< 0.001) and mOS (34.1 months versus 26.8 months, *P* = 0.044) compared with gefitinib, but with increased grade 3 toxicities. In our NMA, S-TKIs was ranked fourth-most effective regimen with moderate risk of causing SAEs.

Based on the findings of this NMA, osimertinib seemed to be the preferable first-line treatment for patients with advanced EGFR-mutated NSCLC. However, the OS data were immature in the FLAURA study \[[@pone.0223530.ref015]\]. The survival rate at 18 months was not significantly longer with osimertinib than with F-TKIs (83% versus 71%) in the interim analysis \[[@pone.0223530.ref015]\]. More recently, postprogression outcomes of the FLAURA study have been reported \[[@pone.0223530.ref048]\]. Median second PFS was not reached \[95% CI, 23.7-not calculable (NC)\] in the osimertinib arm and 20.0 months (95% CI, 18.2-NC) in the standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib) arm \[HR = 0.58, 95% CI: 0.44--0.78; *P* = 0.0004\]. This suggested that osimertinib preserved clinical benefit after first progression. Moreover, median time to discontinuation of any EGFR-TKI or death was 23.0 months (95% CI, 19.5-NC) in the osimertinib arm and 16.0 months (95% CI, 14.8--18.6) in the SoC EGFR-TKI arm. These exploratory postprogression outcomes showed consistent improvements of osimertinib compared to SoC EGFR-TKI, and provide further confidence in the interim OS data.

There are several limitations in this network meta-analysis. First, in common with other meta-analyses, data were collected and analyzed basis of results reported from trials, and not on individual patient data. Therefore, effects of potential prognostic factors could not be accounted for. Second, most of included trials reported an immature OS data, and follow-up times across trials were different and generally short. Moreover, only one RCT investigated efficacy of osimertinib vs F-TKIs. These limitations do not allow us to reach a definitive conclusion about the superiority of one treatment over another. Third, this network meta-analysis included most of RCTs with Asians (15/25). We combined treatment effects for Asians and other groups assuming that there is no racial difference in the treatment effects. However, there was still no evidence supporting that the effect of TKIs among Asians is comparable to that among other racial groups, and we could not investigate such a racial difference in the treatment effect using this network meta-analysis data. Fourth, TKIs efficacy may be associated with patient characteristics (such as gender, race, and smoking status), tumor pathology, EGFR mutation types, and developing brain metastasis or not. However, we could not perform the subgroup-analyses because of insufficient data in the individual trials. Finally, some HRs of PFS or OS were calculated from the Kaplan--Meier curve due to that they were not directly reported in the articles. This may result in bias.

Conclusions {#sec019}
===========

Osimertinib seemed to be the most preferable first-line treatment in advanced EGFR-mutated NSCLC. However, limitations of the study including a single RCT investigating osimertinib and immature OS data need to be considered.
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======================

###### Assessment of risk of bias.

A: Methodological quality graph: authors' judgment about each methodological quality item presented as percentages across all included studies; B: Methodological quality summary: authors' judgment about each methodological quality item for each included study, "+" low risk of bias; "?" unclear risk of bias; "-" high risk of bias.
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Click here for additional data file.

###### Comparison-adjusted funnel plots of publication bias test for progression-free survival.

TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.

(TIF)
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Click here for additional data file.

###### Inconsistency evaluation by node-splitting analyses.

\(a\) progression-free survival; (b) overall survival; (c) serious adverse events. TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; CT, chemotherapy.

(TIF)
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